Case Study

  • A Life Science Park for giants – Selvita S.A.

    Selvita S.A. is an excellent example of creating synergies - it benefits from EU funds, well-educated staff, and the fact of being located in the Life Science Park.
  • JCI makes beginnings easier for new businesses

    Jagiellonian Center of Innovation has developed a model of cooperation between the partners in a company who want support in carrying out research work based on external resources.
  • Business in Biotechnology studies - without borders

    Postgraduate studies "Business in Biotechnology" have been launched at the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University in Krakow.
  • Salmonella for cancer therapy

    The first application for funding for the Jagiellonian University/JCI consortium in the life sciences received funding from the INNOTECH programme of the Polish National Centre for Research and Development (NCBIR).

A Life Science Park for giants – Selvita S.A.

Selvita S.A. is an excellent example of creating synergies - it benefits from EU funds, well-educated staff, and the fact of being located in the Life Science Park.
Selvita is a Polish research and development company founded in 2007 in Krakow. Its mission and main objects is to provide comprehensive solutions in the field of biotechnology and bioinformatics for research and development units to reduce the cost of bringing innovative products to market.
The company pursues its objectives it by running their own projects for the development of the original chemical molecules with therapeutic properties, providing research and development services to the biotechnology and pharmaceutical industry, creating innovative and cost-effective IT solutions to accelerate research and reduce the risk of failure, and to ensuring that the outsourcing model includes qualified teams research and development teams, specialized in specific areas of the process of introducing new substances on the market.

In addition, Selvita conducts its own research projects aimed at developing original chemical molecules with therapeutic properties in the area of oncology, central nervous system disorders, and autoimmune diseases. The innovative structure of the company is the result of research work carried out at Polish universities, as well as Selvita's own projects.

Selvita develops projects to the stage of completion of pre-clinical studies, and further work on the project is conducted in collaboration with a strategic partner, i.e. with leading Polish and international pharmaceutical companies. The company has been present in the Life Science Park since 2009. During that time, the surface it rents from JCI has increased from 80 to more than 700 square metres.






JCI makes beginnings easier for new businesses

Jagiellonian Center of Innovation has developed a model of cooperation between the partners in a company who want support in carrying out research work based on external resources.
Jagiellonian Center of Innovation has developed a model of cooperation between the partners in a company who want support in carrying out research work based on external resources.

JCI Venture fund portfolio company - novel-iD - has been a tenant in the Life Science Park since January 2012. The company operates at the interface of pharmaceutics and nanotechnology for customers in the pharmaceutical and cosmetic industries. It has proprietary solutions in the field of pharmaceutical nanotechnology. On the basis of a dedicated liposomal platform, it delivers active ingredients, and offers improved efficiency of pharmaceutical and cosmetic products, by increasing the solubility of the active substance, effectively delivering API for the therapeutic target, as well as reducing any potential side effects associated with the treatment.

The company uses its laboratory equipment, part of which was purchased from the seed capital of JCI Venture, not only for its own purposes. It carries out research commissioned by external entities, works with universities and businesses unrelated to JCI, and subleases the laboratory "by the hour". Thanks to those solutions, its resources are used to the maximum extent, and the company secures an additional source of revenue. Importantly, JCI is often an intermediary representing novel-iD at business meetings.

The business model described above also facilitates the start of a business for other JCI partners where they do not have sufficient funds to purchase equipment and run their own lab. It works particularly well with regard to research projects and companies that are at a very early stage of development.

Jagiellonian Center of Innovation uses a similar strategy for the research resources deposited in the universities of Krakow, with their range being much wider, however.

Business in Biotechnology studies - without borders

Postgraduate studies "Business in Biotechnology" have been launched at the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University in Krakow.
Postgraduate studies "Business in Biotechnology" have been launched at the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University in Krakow. They are carried out in a consortium between the Jagiellonian University and JCI, the latter acting as project leader.
"The idea to create interdisciplinary postgraduate studies in Business in Biotechnology was born as a need of the times. For many years now, we have been observing the paths in the lives of biotechnology graduates, the main specialization of the Department, and seeing how many of them, unfortunately, leave Poland, seeking their fortune in foreign research centres and biotechnology companies. From the point of view of our country, it is a waste - talented, well-educated people cannot find their professional niche at home. One of the objectives of the postgraduate studies in Business in Biotechnology is to help create new jobs by assisting in the establishment of companies that would constitute a reasonable alternative to emigration in search of employment", says Dr Tomasz Panz, head of postgraduate studies in Business in Biotechnology.
The studies have been launched at the Department of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University in Krakow, and are carried out in a consortium with Jagiellońskie Centrum Innowacji (JCI being the leader).
The studies focus on the issue of technology transfer from universities to the economy, the commercialization of scientific research, and running a business related to the life science industry, in particular biotechnology.
The project is implemented with the participation of selected Polish universities which teach in the field of biotechnology. Their main role is to promote the studies regionally, coordinate activities on a local scale, and provide information on the studies to students from the region. The partner universities hold video-conference classes, which allows students to participate in lectures without having to travel to Krakow.
The overall objective of the studies is to educate a group of managers / scientists prepared to conduct a business oriented at technology transfer and commercialization of research. In addition, the curriculum contains a strong focus on the transfer of knowledge about the practical aspects of doing business in the life science industry (enterprise organization and management), with particular emphasis on biotechnology and intensive implementation of technology transfer and innovation management processes.
The studies take two semesters, including 80 hours of lectures and 20 hours of practical training in each semester. Each lecture session is divided into theoretical and practical parts. The practical session is mainly devoted to case studies and logic games referring to the earlier lecture.
The lecturers are mostly practitioners (managers, members of management teams) who are developing companies in the life sciences in Poland and abroad, as well as researchers at the Jagiellonian University. Due to the need for proper preparation of the students as well as their diverse educational background, the first module has been divided - the classes are taught in two parallel groups. The first consists of persons with biotechnological education, and the second - with an economic background.

Salmonella for cancer therapy

The first application for funding for the Jagiellonian University/JCI consortium in the life sciences received funding from the INNOTECH programme of the Polish National Centre for Research and Development (NCBIR).
The first application for funding for the Jagiellonian University/JCI consortium in the life sciences received funding from the INNOTECH programme of the Polish National Centre for Research and Development (NCBIR). In June 2011, the Jagiellonian University/JCI consortium in Krakow, founded under the GRANTY (GRANTS) programme, applied to NCBiR for funding of a research project under the INNOTECH programme. The project was called "New cancer therapy based on a genetically modified strain of Salmonella".

The aim of the project is to prepare the implementation of a new method of treating cancer using a genetically modified intracellular pathogen - Salmonella enterica s. Typhimurium. The proposed therapy demonstrates therapeutic effect through direct toxic action of bacteria on cancer cells and providing a signal that stimulates the immune system. The project - based on original research and inventions of the Jagiellonian University - assumes genetic optimization of a bacterial strain, improvement of its effectiveness, as well as an analysis of toxicity, dose and route of administration of the therapeutic product. The amount requested by the consortium was more than PLN 4 million. On 27 January 2012, NCBiR agreed to grant the funding.

The first phase of the project - the research phase - will be carried out at the Department of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Contributions have also been offered by other units of the Jagiellonian University, whose activities support the research projects of the Department of Biochemistry, Biophysics and Biotechnology. For example, the Centre for Innovation, Technology Transfer and University Development (CITTRU), which is a specialized unit of the central administration of the Jagiellonian University, will assist in the protection of intellectual property, as well as provide support in the promotion of project results, possible collaboration with the pharmaceutical and biotechnological industry, and other activities in the field of technology transfer.
At that stage, Jagiellonian Center of Innovation is responsible for analysis of the commercial aspects of the research phase (JCI will organize expert consultations concerning the research materials and tools to be used), project coordination (the company will be responsible for proper execution and coordination of research phase tasks and will provide financing management in accordance with the best practice in project implementation), and verification of the research results (by obtaining external expert opinions).
Upon successful completion of the research phase, the consortium partners will take action to establish a special purpose vehicle (SPV) and will take up its shares in exchange for the results generated during the project (contribution). It is assumed that one of the shareholders will be JCI, together with its subsidiary and protégé seed funds and venture capital. The money invested will allow further development of the project during the initial stages of its activity. The next stages of research and development may, in turn, be financed by additional financial investors or industry partners.

Contact person:
Justyna Morawska-Płoskonka
T: +48 12 297 46 12 | K: +48 512 032 476
F: +48 12 297 46 46 | E:  justyna.morawska@jci.pl